Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist-Reference-Cited by-同舟云学术

Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist

Published:2022-06-02 Issue:12 Volume:65 Page:8127-8143
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Iijima Toru¹²^ORCID,Katoh Makoto¹,Takedomi Kei¹^ORCID,Yamamoto Yasuo¹,Akatsuka Hidenori¹,Shirata Naritoshi¹,Nishi Akito¹,Takakuwa Misae¹,Watanabe Yoshinori¹,Munakata Hitomi¹,Koyama Naomi¹,Ikeda Tomoko¹,Iguchi Taku¹,Kato Harutoshi¹,Kikkawa Kohei¹,Kawaguchi Takayuki¹

Affiliation:

1. Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 1000 Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan

2. Lead Exploration Unit, Drug Discovery Initiative, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00402

Reference49 articles.

1. The Steroid and Thyroid Hormone Receptor Superfamily

2. Aldosterone: Its Receptor, Target Genes, and Actions

3. Extrarenal effects of aldosterone

4. Aldosterone and the heart: towards a physiological function?

5. Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trials;Drug Metabolism and Pharmacokinetics;2024-06

2. The Thin Line between Promiscuous and Privileged Structures in Medicinal Chemistry;Journal of the Brazilian Chemical Society;2024

3. Personalized Treatment of Patients With Primary Aldosteronism;Endocrine Practice;2022-10

4. Novel strategies in nephrology: what to expect from the future?;Clinical Kidney Journal;2022-09-20